ALCAM (CD166) expression and serum levels are markers for poor survival of esophageal cancer patients

The expression of the activated leukocyte cell adhesion molecule (ALCAM and CD166) is increased in various types of cancer. We aimed to evaluate its role as a prognostic marker for esophageal cancer (EC). We retrospectively analyzed ALCAM expression in 299 primary lesions, 147 lymph node and 46 dist...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of cancer Vol. 131; no. 2; pp. 396 - 405
Main Authors Tachezy, Michael, Effenberger, Katharina, Zander, Hilke, Minner, Sarah, Gebauer, Florian, Vashist, Yogesh K., Sauter, Guido, Pantel, Klaus, Izbicki, Jakob R., Bockhorn, Maximilian
Format Journal Article
LanguageEnglish
Published Hoboken Wiley Subscription Services, Inc., A Wiley Company 15.07.2012
Wiley-Blackwell
Wiley Subscription Services, Inc
Subjects
Activated-Leukocyte Cell Adhesion Molecule - blood
Activated-Leukocyte Cell Adhesion Molecule - metabolism
Adult
Aged
Aged, 80 and over
ALCAM
Biological and medical sciences
biomarker
Biomarkers
Biomarkers, Tumor - blood
Biomarkers, Tumor - metabolism
Bone marrow
Cancer
Esophageal cancer
Esophageal Neoplasms - metabolism
Esophageal Neoplasms - mortality
Esophageal Neoplasms - pathology
Esophagus
Female
Gastroenterology. Liver. Pancreas. Abdomen
Humans
Immunohistochemistry
Keratins - analysis
Male
Medical research
Medical sciences
Middle Aged
Mortality
Multivariate analysis
Neoplasm Grading
Prognosis
Protein Array Analysis
Retrospective Studies
Tumors
Human
Prognosis
esophageal cancer
Esophageal disease
Cell adhesion molecule
Biological marker
Malignant tumor
biomarker
Survival
Esophagus cancer
Cancerology
ALCAM
Digestive diseases
Activated leukocyte cell adhesion molecule
Serum
Cancer
Online AccessGet full text
ISSN0020-7136
1097-0215
1097-0215
DOI10.1002/ijc.26377

Cover

Abstract The expression of the activated leukocyte cell adhesion molecule (ALCAM and CD166) is increased in various types of cancer. We aimed to evaluate its role as a prognostic marker for esophageal cancer (EC). We retrospectively analyzed ALCAM expression in 299 primary lesions, 147 lymph node and 46 distant metastases from EC patients, on a tissue microarray using immunohistochemistry. Bone marrow samples from representative cancer patients (n = 16), taken before primary surgery, were stained by double‐immunofluorescence for ALCAM and cytokeratins (CK). Blood serum samples from 236 cancer patients and 127 controls were analyzed for serum ALCAM (s‐ALCAM) by ELISA. The immunohistochemical analysis showed increased ALCAM expression in the majority of lesions (primary tumor 71%, lymph node 76% and distant metastases 80%). ALCAM expression was not associated with histopathological parameters except for tumor grading (p = 0.015). ALCAM‐positive patients had significantly worse recurrence‐free and overall survival (OS; p = 0.002). Disseminated tumor cells (DTC) in bone marrow showed two phenotypes, ALCAM+/CK+ (36%) and ALCAM‐/CK+ (64%). Multivariate analysis revealed that ALCAM expression and elevated s‐ALCAM serum values are powerful prognostic variables for OS in patients with EC (hazard ratio [HR] 3.987, 95% confidence interval [95%CI] 1.906–8.340, p < 0.001 and HR 1.915, 95%CI 1.021–3.592, p = 0.043). The results of our study provide preliminary evidence for the potential clinical utility of ALCAM as a prognostic biomarker for EC, which might be a basis for future clinical application. In addition, ALCAM expression in a subset of DTC of the bone marrow indicates a potential function in the metastatic cascade of EC.
AbstractList The expression of the activated leukocyte cell adhesion molecule (ALCAM and CD166) is increased in various types of cancer. We aimed to evaluate its role as a prognostic marker for esophageal cancer (EC). We retrospectively analyzed ALCAM expression in 299 primary lesions, 147 lymph node and 46 distant metastases from EC patients, on a tissue microarray using immunohistochemistry. Bone marrow samples from representative cancer patients (n = 16), taken before primary surgery, were stained by double-immunofluorescence for ALCAM and cytokeratins (CK). Blood serum samples from 236 cancer patients and 127 controls were analyzed for serum ALCAM (s-ALCAM) by ELISA. The immunohistochemical analysis showed increased ALCAM expression in the majority of lesions (primary tumor 71%, lymph node 76% and distant metastases 80%). ALCAM expression was not associated with histopathological parameters except for tumor grading (p = 0.015). ALCAM-positive patients had significantly worse recurrence-free and overall survival (OS; p = 0.002). Disseminated tumor cells (DTC) in bone marrow showed two phenotypes, ALCAM+/CK+ (36%) and ALCAM-/CK+ (64%). Multivariate analysis revealed that ALCAM expression and elevated s-ALCAM serum values are powerful prognostic variables for OS in patients with EC (hazard ratio [HR] 3.987, 95% confidence interval [95%CI] 1.906-8.340, p < 0.001 and HR 1.915, 95%CI 1.021-3.592, p = 0.043). The results of our study provide preliminary evidence for the potential clinical utility of ALCAM as a prognostic biomarker for EC, which might be a basis for future clinical application. In addition, ALCAM expression in a subset of DTC of the bone marrow indicates a potential function in the metastatic cascade of EC.
The expression of the activated leukocyte cell adhesion molecule (ALCAM and CD166) is increased in various types of cancer. We aimed to evaluate its role as a prognostic marker for esophageal cancer (EC). We retrospectively analyzed ALCAM expression in 299 primary lesions, 147 lymph node and 46 distant metastases from EC patients, on a tissue microarray using immunohistochemistry. Bone marrow samples from representative cancer patients ( n = 16), taken before primary surgery, were stained by double‐immunofluorescence for ALCAM and cytokeratins (CK). Blood serum samples from 236 cancer patients and 127 controls were analyzed for serum ALCAM (s‐ALCAM) by ELISA. The immunohistochemical analysis showed increased ALCAM expression in the majority of lesions (primary tumor 71%, lymph node 76% and distant metastases 80%). ALCAM expression was not associated with histopathological parameters except for tumor grading ( p = 0.015). ALCAM‐positive patients had significantly worse recurrence‐free and overall survival (OS; p = 0.002). Disseminated tumor cells (DTC) in bone marrow showed two phenotypes, ALCAM+/CK+ (36%) and ALCAM‐/CK+ (64%). Multivariate analysis revealed that ALCAM expression and elevated s‐ALCAM serum values are powerful prognostic variables for OS in patients with EC (hazard ratio [HR] 3.987, 95% confidence interval [95%CI] 1.906–8.340, p < 0.001 and HR 1.915, 95%CI 1.021–3.592, p = 0.043). The results of our study provide preliminary evidence for the potential clinical utility of ALCAM as a prognostic biomarker for EC, which might be a basis for future clinical application. In addition, ALCAM expression in a subset of DTC of the bone marrow indicates a potential function in the metastatic cascade of EC.
The expression of the activated leukocyte cell adhesion molecule (ALCAM and CD166) is increased in various types of cancer. We aimed to evaluate its role as a prognostic marker for esophageal cancer (EC). We retrospectively analyzed ALCAM expression in 299 primary lesions, 147 lymph node and 46 distant metastases from EC patients, on a tissue microarray using immunohistochemistry. Bone marrow samples from representative cancer patients (n = 16), taken before primary surgery, were stained by double-immunofluorescence for ALCAM and cytokeratins (CK). Blood serum samples from 236 cancer patients and 127 controls were analyzed for serum ALCAM (s-ALCAM) by ELISA. The immunohistochemical analysis showed increased ALCAM expression in the majority of lesions (primary tumor 71%, lymph node 76% and distant metastases 80%). ALCAM expression was not associated with histopathological parameters except for tumor grading (p = 0.015). ALCAM-positive patients had significantly worse recurrence-free and overall survival (OS; p = 0.002). Disseminated tumor cells (DTC) in bone marrow showed two phenotypes, ALCAM+/CK+ (36%) and ALCAM-/CK+ (64%). Multivariate analysis revealed that ALCAM expression and elevated s-ALCAM serum values are powerful prognostic variables for OS in patients with EC (hazard ratio [HR] 3.987, 95% confidence interval [95%CI] 1.906-8.340, p < 0.001 and HR 1.915, 95%CI 1.021-3.592, p = 0.043). The results of our study provide preliminary evidence for the potential clinical utility of ALCAM as a prognostic biomarker for EC, which might be a basis for future clinical application. In addition, ALCAM expression in a subset of DTC of the bone marrow indicates a potential function in the metastatic cascade of EC. [PUBLICATION ABSTRACT]
The expression of the activated leukocyte cell adhesion molecule (ALCAM and CD166) is increased in various types of cancer. We aimed to evaluate its role as a prognostic marker for esophageal cancer (EC). We retrospectively analyzed ALCAM expression in 299 primary lesions, 147 lymph node and 46 distant metastases from EC patients, on a tissue microarray using immunohistochemistry. Bone marrow samples from representative cancer patients (n = 16), taken before primary surgery, were stained by double-immunofluorescence for ALCAM and cytokeratins (CK). Blood serum samples from 236 cancer patients and 127 controls were analyzed for serum ALCAM (s-ALCAM) by ELISA. The immunohistochemical analysis showed increased ALCAM expression in the majority of lesions (primary tumor 71%, lymph node 76% and distant metastases 80%). ALCAM expression was not associated with histopathological parameters except for tumor grading (p = 0.015). ALCAM-positive patients had significantly worse recurrence-free and overall survival (OS; p = 0.002). Disseminated tumor cells (DTC) in bone marrow showed two phenotypes, ALCAM+/CK+ (36%) and ALCAM-/CK+ (64%). Multivariate analysis revealed that ALCAM expression and elevated s-ALCAM serum values are powerful prognostic variables for OS in patients with EC (hazard ratio [HR] 3.987, 95% confidence interval [95%CI] 1.906-8.340, p < 0.001 and HR 1.915, 95%CI 1.021-3.592, p = 0.043). The results of our study provide preliminary evidence for the potential clinical utility of ALCAM as a prognostic biomarker for EC, which might be a basis for future clinical application. In addition, ALCAM expression in a subset of DTC of the bone marrow indicates a potential function in the metastatic cascade of EC.The expression of the activated leukocyte cell adhesion molecule (ALCAM and CD166) is increased in various types of cancer. We aimed to evaluate its role as a prognostic marker for esophageal cancer (EC). We retrospectively analyzed ALCAM expression in 299 primary lesions, 147 lymph node and 46 distant metastases from EC patients, on a tissue microarray using immunohistochemistry. Bone marrow samples from representative cancer patients (n = 16), taken before primary surgery, were stained by double-immunofluorescence for ALCAM and cytokeratins (CK). Blood serum samples from 236 cancer patients and 127 controls were analyzed for serum ALCAM (s-ALCAM) by ELISA. The immunohistochemical analysis showed increased ALCAM expression in the majority of lesions (primary tumor 71%, lymph node 76% and distant metastases 80%). ALCAM expression was not associated with histopathological parameters except for tumor grading (p = 0.015). ALCAM-positive patients had significantly worse recurrence-free and overall survival (OS; p = 0.002). Disseminated tumor cells (DTC) in bone marrow showed two phenotypes, ALCAM+/CK+ (36%) and ALCAM-/CK+ (64%). Multivariate analysis revealed that ALCAM expression and elevated s-ALCAM serum values are powerful prognostic variables for OS in patients with EC (hazard ratio [HR] 3.987, 95% confidence interval [95%CI] 1.906-8.340, p < 0.001 and HR 1.915, 95%CI 1.021-3.592, p = 0.043). The results of our study provide preliminary evidence for the potential clinical utility of ALCAM as a prognostic biomarker for EC, which might be a basis for future clinical application. In addition, ALCAM expression in a subset of DTC of the bone marrow indicates a potential function in the metastatic cascade of EC.
Author Pantel, Klaus
Izbicki, Jakob R.
Sauter, Guido
Tachezy, Michael
Bockhorn, Maximilian
Minner, Sarah
Zander, Hilke
Vashist, Yogesh K.
Effenberger, Katharina
Gebauer, Florian
Author_xml – sequence: 1
  givenname: Michael
  surname: Tachezy
  fullname: Tachezy, Michael
  email: mtachezy@uke.uni-hamburg.de
  organization: Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg Eppendorf, Hamburg, Germany
– sequence: 2
  givenname: Katharina
  surname: Effenberger
  fullname: Effenberger, Katharina
  organization: Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg Eppendorf, Hamburg, Germany
– sequence: 3
  givenname: Hilke
  surname: Zander
  fullname: Zander, Hilke
  organization: Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg Eppendorf, Hamburg, Germany
– sequence: 4
  givenname: Sarah
  surname: Minner
  fullname: Minner, Sarah
  organization: Department of Pathology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
– sequence: 5
  givenname: Florian
  surname: Gebauer
  fullname: Gebauer, Florian
  organization: Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg Eppendorf, Hamburg, Germany
– sequence: 6
  givenname: Yogesh K.
  surname: Vashist
  fullname: Vashist, Yogesh K.
  organization: Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg Eppendorf, Hamburg, Germany
– sequence: 7
  givenname: Guido
  surname: Sauter
  fullname: Sauter, Guido
  organization: Department of Pathology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
– sequence: 8
  givenname: Klaus
  surname: Pantel
  fullname: Pantel, Klaus
  organization: Department of Tumor Biology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
– sequence: 9
  givenname: Jakob R.
  surname: Izbicki
  fullname: Izbicki, Jakob R.
  organization: Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg Eppendorf, Hamburg, Germany
– sequence: 10
  givenname: Maximilian
  surname: Bockhorn
  fullname: Bockhorn, Maximilian
  organization: Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg Eppendorf, Hamburg, Germany
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25981739$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/21858815$$D View this record in MEDLINE/PubMed
BookMark eNp9kVFv0zAUhS00xLpuD_wBZAkhbQ_ZfOM4Th5LYGWoGy9M481ynRtwSePMTsr27_FoN6RJ8OIr637nyD7ngOx1rkNCXgM7BcbSM7syp2nOpXxBJsBKmbAUxB6ZxB1LJPB8nxyEsGIMQLDsFdlPoRBFAWJCcLaoZpf0uPoAeX5C8a73GIJ1HdVdTQP6cU1b3GAbqPZI19r_RB9o4zztXTzC6Dd2o1vqGorB9T_0d4w3ozuDEdGDxW4Ih-Rlo9uAR7s5JdfnH79Wn5LFl_lFNVskJiukTLAADsi0LtLc8Lpmy2UhtEDDTc0EN0tW5rnmWkuTmQyzWvNMYAkFy-uUS86n5Hjr23t3O2IY1NoGg22rO3RjUMBASCFEDGtK3j5DV270XXydgoxzgJJBGak3O2pcrrFWvbcxgnv1GGAE3u0AHYxuGx8_bsNfTpQFSP5gdLLljHcheGyeEGDqoUQVS1R_Sozs2TPW2CEm6brBa9v-T_HLtnj_b2t18bl6VCRbhQ0D3j0pYr0ql1wKdXM1V--_XZ3z9GauFvw3uQu5xA
CODEN IJCNAW
CitedBy_id crossref_primary_10_18632_oncotarget_2651
crossref_primary_10_18632_oncotarget_27525
crossref_primary_10_1080_14737159_2016_1211932
crossref_primary_10_1097_BS9_0000000000000109
crossref_primary_10_1164_rccm_201703_0532OC
crossref_primary_10_1186_s13075_020_02209_9
crossref_primary_10_4103_ejh_ejh_5_23
crossref_primary_10_2188_jea_JE20140118
crossref_primary_10_1242_bio_061729
crossref_primary_10_1371_journal_pone_0070958
crossref_primary_10_1016_j_semcancer_2019_12_024
crossref_primary_10_1158_0008_5472_CAN_12_2052
crossref_primary_10_18632_oncotarget_13546
crossref_primary_10_1002_stem_1665
crossref_primary_10_1089_cbr_2019_3089
crossref_primary_10_3390_cancers13205187
crossref_primary_10_3389_fonc_2017_00080
crossref_primary_10_1002_pmic_201200356
crossref_primary_10_1016_j_biopha_2015_12_006
crossref_primary_10_18632_oncotarget_24625
crossref_primary_10_18632_oncotarget_27279
crossref_primary_10_1089_thy_2012_0405
crossref_primary_10_1016_j_bbapap_2013_01_030
crossref_primary_10_1158_0008_5472_CAN_13_1296
crossref_primary_10_1186_1479_5876_11_238
crossref_primary_10_1155_2015_321740
crossref_primary_10_1177_17246008211005473
crossref_primary_10_3892_mmr_2014_2933
crossref_primary_10_1016_j_lungcan_2014_11_017
crossref_primary_10_1007_s11684_013_0286_y
crossref_primary_10_1093_neuonc_noaa028
crossref_primary_10_1021_ac503374j
crossref_primary_10_1074_mcp_M112_025460
crossref_primary_10_1136_jitc_2019_000172
crossref_primary_10_3892_or_2015_3818
Cites_doi 10.1038/modpathol.3800712
10.1016/j.oraloncology.2010.03.001
10.1159/000086989
10.1002/pros.10161
10.1016/j.trsl.2007.09.006
10.1158/1541-7786.MCR-07-0060
10.1016/j.bios.2008.11.015
10.1097/SLA.0b013e3181904f3c
10.1016/j.gie.2007.03.1051
10.1056/NEJM199905273402116
10.1016/j.ccr.2008.04.005
10.1016/j.soc.2009.09.007
10.1056/NEJM200002243420801
10.1002/ijc.25196
10.1245/s10434-008-0169-7
10.1038/sj.bjc.6605136
10.1093/jnci/88.17.1222
10.1007/s00216-008-2448-3
10.1158/0008-5472.CAN-07-5767
10.1002/ijc.24292
10.4161/cc.8.20.9699
10.1093/jnci/86.11.829
10.1038/modpathol.2008.104
10.1002/jso.20544
10.1093/jnci/dji431
10.1002/jso.21479
10.1136/jcp.2004.016238
10.1055/s-2007-966655
10.1007/s10549-007-9879-y
10.1158/1078-0432.CCR-07-0428
10.1038/modpathol.3800547
ContentType Journal Article
Copyright Copyright © 2011 UICC
2015 INIST-CNRS
Copyright © 2011 UICC.
Copyright_xml – notice: Copyright © 2011 UICC
– notice: 2015 INIST-CNRS
– notice: Copyright © 2011 UICC.
DBID BSCLL
AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7T5
7TO
7U9
H94
K9.
7X8
DOI 10.1002/ijc.26377
DatabaseName Istex
CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Immunology Abstracts
Oncogenes and Growth Factors Abstracts
Virology and AIDS Abstracts
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Immunology Abstracts
Virology and AIDS Abstracts
Oncogenes and Growth Factors Abstracts
MEDLINE - Academic
DatabaseTitleList MEDLINE
CrossRef
AIDS and Cancer Research Abstracts
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1097-0215
EndPage 405
ExternalDocumentID 3073974441
21858815
25981739
10_1002_ijc_26377
IJC26377
ark_67375_WNG_BXNF32WG_L
Genre article
Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: Forschungsförderungsfond‐Nachwuchsförderung 2011
– fundername: Dr. Mildred Scheel Stiftung fuer Krebsforschung (Deutsche Krebshilfe e. V.)
GroupedDBID ---
-~X
.3N
.GA
.Y3
05W
0R~
10A
1L6
1OB
1OC
1ZS
33P
3SF
3WU
4.4
4ZD
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
5GY
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHQN
AAIPD
AAMMB
AAMNL
AANLZ
AAONW
AASGY
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABIJN
ABJNI
ABLJU
ABOCM
ABPVW
ABQWH
ABXGK
ACAHQ
ACCZN
ACFBH
ACGFO
ACGFS
ACGOF
ACIWK
ACMXC
ACPOU
ACPRK
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
AEFGJ
AEGXH
AEIGN
AEIMD
AENEX
AEUYR
AEYWJ
AFBPY
AFFPM
AFGKR
AFRAH
AFWVQ
AFZJQ
AGXDD
AGYGG
AHBTC
AHMBA
AIACR
AIAGR
AIDQK
AIDYY
AITYG
AIURR
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ATUGU
AZBYB
AZVAB
BAFTC
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BSCLL
BY8
C45
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EBS
EJD
EMOBN
F00
F01
F04
F5P
FUBAC
G-S
G.N
GNP
GODZA
H.X
HBH
HF~
HGLYW
HHY
HHZ
HZ~
IH2
IX1
J0M
JPC
KBYEO
KQQ
L7B
LATKE
LAW
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
NNB
O66
O9-
OIG
OK1
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PQQKQ
Q.N
Q11
QB0
QRW
R.K
RIWAO
RJQFR
ROL
RX1
RYL
SUPJJ
TEORI
UB1
UDS
V2E
V8K
V9Y
W2D
W8V
W99
WBKPD
WHWMO
WIB
WIH
WIJ
WIK
WJL
WOHZO
WQJ
WVDHM
WXI
WXSBR
XG1
XPP
XV2
ZZTAW
~IA
~WT
24P
AAHHS
ACCFJ
ADZOD
AEEZP
AEQDE
AEUQT
AFPWT
AIWBW
AJBDE
RWI
WIN
WRC
WUP
WWO
AAYXX
CITATION
.55
.GJ
31~
3O-
53G
8WZ
A6W
AANHP
ABEFU
ABEML
ACBWZ
ACRPL
ACSCC
ACYXJ
ADNMO
AGHNM
AGQPQ
AHEFC
AI.
ASPBG
AVWKF
AZFZN
BDRZF
EX3
FEDTE
GLUZI
HVGLF
IQODW
M6P
PALCI
SAMSI
VH1
WOW
X7M
Y6R
ZGI
ZXP
CGR
CUY
CVF
ECM
EIF
NPM
7T5
7TO
7U9
H94
K9.
7X8
ID FETCH-LOGICAL-c4877-e8131e0aa826c3dd0bb85a5ec3cd053cb0966a3aa7c4c4e4da345e91806d23733
IEDL.DBID DR2
ISSN 0020-7136
1097-0215
IngestDate Thu Jul 10 23:46:06 EDT 2025
Fri Jul 25 04:27:24 EDT 2025
Mon Jul 21 06:03:46 EDT 2025
Mon Jul 21 09:14:37 EDT 2025
Tue Jul 01 02:27:38 EDT 2025
Thu Apr 24 23:07:57 EDT 2025
Wed Jan 22 16:28:51 EST 2025
Sun Sep 21 06:19:33 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords Human
Prognosis
esophageal cancer
Esophageal disease
Cell adhesion molecule
Biological marker
Malignant tumor
biomarker
Survival
Esophagus cancer
Cancerology
ALCAM
Digestive diseases
Activated leukocyte cell adhesion molecule
Serum
Cancer
Language English
License http://onlinelibrary.wiley.com/termsAndConditions#vor
CC BY 4.0
Copyright © 2011 UICC.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4877-e8131e0aa826c3dd0bb85a5ec3cd053cb0966a3aa7c4c4e4da345e91806d23733
Notes ArticleID:IJC26377
M.T. and K.E. contributed equally to this work
Forschungsförderungsfond-Nachwuchsförderung 2011
Our study was presented in 2010 at the 10th World Congress of the World Organization for Specialized Studies on Diseases of the Esophagus (OESO).
Dr. Mildred Scheel Stiftung fuer Krebsforschung (Deutsche Krebshilfe e. V.)
ark:/67375/WNG-BXNF32WG-L
istex:5AC6FF0794CD50B0A3D494AAADBDE987E0F563FA
Tel.: 49‐40‐7410‐52401, Fax: +49‐40‐7410‐54995
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
PMID 21858815
PQID 1433119019
PQPubID 105430
PageCount 10
ParticipantIDs proquest_miscellaneous_1015755526
proquest_journals_1433119019
pubmed_primary_21858815
pascalfrancis_primary_25981739
crossref_primary_10_1002_ijc_26377
crossref_citationtrail_10_1002_ijc_26377
wiley_primary_10_1002_ijc_26377_IJC26377
istex_primary_ark_67375_WNG_BXNF32WG_L
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 15 July 2012
PublicationDateYYYYMMDD 2012-07-15
PublicationDate_xml – month: 07
  year: 2012
  text: 15 July 2012
  day: 15
PublicationDecade 2010
PublicationPlace Hoboken
PublicationPlace_xml – name: Hoboken
– name: Hoboken, NJ
– name: United States
PublicationTitle International journal of cancer
PublicationTitleAlternate Int. J. Cancer
PublicationYear 2012
Publisher Wiley Subscription Services, Inc., A Wiley Company
Wiley-Blackwell
Wiley Subscription Services, Inc
Publisher_xml – name: Wiley Subscription Services, Inc., A Wiley Company
– name: Wiley-Blackwell
– name: Wiley Subscription Services, Inc
References Barnett SA, Rizk NP. Randomized clinical trials in esophageal carcinoma. Surg Oncol Clin N Am 2010; 19: 59-80.
Rawnaq T, Kleinhans H, Uto M, Schurr PG, Reichelt U, Cataldegirmen G, Gawad KA, Yekebas EF, Schachner M, Izbicki JR, Kaifi JT. Subset of esophageal adenocarcinoma expresses adhesion molecule l1 in contrast to squamous cell carcinoma. Anticancer Res 2009; 29: 1195-9.
Reichelt U, Duesedau P, Tsourlakis M, Quaas A, Link BC, Schurr PG, Kaifi JT, Gros SJ, Yekebas EF, Marx A, Simon R, Izbicki JR, et al. Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol 2007; 20: 120-9.
Koenig AM, Prenzel KL, Bogoevski D, Yekebas EF, Bubenheim M, Faithova L, Vashist YK, Gawad KA, Baldus SE, Pantel K, Schneider PM, Holscher AH, et al. Strong impact of micrometastatic tumor cell load in patients with esophageal carcinoma. Ann Surg Oncol 2009; 16: 454-62.
Kaifi JT, Strelow A, Schurr PG, Reichelt U, Yekebas EF, Wachowiak R, Quaas A, Strate T, Schaefer H, Sauter G, Schachner M, Izbicki JR. L1 (CD171) is highly expressed in gastrointestinal stromal tumors. Mod Pathol 2006; 19: 399-406.
Kalinina T, Bockhorn M, Kaifi JT, Thieltges S, Gungor C, Effenberger KE, Strelow A, Reichelt U, Sauter G, Pantel K, Izbicki JR, Yekebas EF. Insulin-like growth factor-1 receptor as a novel prognostic marker and its implication as a cotarget in the treatment of human adenocarcinoma of the esophagus. Int J Cancer 2010; 127: 1931-40.
Vaisocherova H, Faca VM, Taylor AD, Hanash S, Jiang S. Comparative study of SPR and ELISA methods based on analysis of CD166/ALCAM levels in cancer and control human sera. Biosens Bioelectron 2009; 24: 2143-8.
Stoecklein NH, Hosch SB, Bezler M, Stern F, Hartmann CH, Vay C, Siegmund A, Scheunemann P, Schurr P, Knoefel WT, Verde PE, Reichelt U, et al. Direct genetic analysis of single disseminated cancer cells for prediction of outcome and therapy selection in esophageal cancer. Cancer Cell 2008; 13: 441-53.
Mezzanzanica D, Fabbi M, Bagnoli M, Staurengo S, Losa M, Balladore E, Alberti P, Lusa L, Ditto A, Ferrini S, Pierotti MA, Barbareschi M, et al. Subcellular localization of activated leukocyte cell adhesion molecule is a molecular predictor of survival in ovarian carcinoma patients. Clin Cancer Res 2008; 14: 1726-33.
Ihnen M, Muller V, Wirtz RM, Schroder C, Krenkel S, Witzel I, Lisboa BW, Janicke F, Milde-Langosch K. Predictive impact of activated leukocyte cell adhesion molecule (ALCAM/CD166) in breast cancer. Breast Cancer Res Treat 2008; 112: 419-27.
Rosso O, Piazza T, Bongarzone I, Rossello A, Mezzanzanica D, Canevari S, Orengo AM, Puppo A, Ferrini S, Fabbi M. The ALCAM shedding by the metalloprotease ADAM17/TACE is involved in motility of ovarian carcinoma cells. Mol Cancer Res 2007; 5: 1246-53.
Peyre CG, Hagen JA, DeMeester SR, Van Lanschot JJ, Holscher A, Law S, Ruol A, Ancona E, Griffin SM, Altorki NK, Rice TW, Wong J, et al. Predicting systemic disease in patients with esophageal cancer after esophagectomy: a multinational study on the significance of the number of involved lymph nodes. Ann Surg 2008; 248: 979-85.
Shimpi RA, George J, Jowell P, Gress FG. Staging of esophageal cancer by EUS: staging accuracy revisited. Gastrointest Endosc 2007; 66: 475-82.
Kahlert C, Weber H, Mogler C, Bergmann F, Schirmacher P, Kenngott HG, Matterne U, Mollberg N, Rahbari NN, Hinz U, Koch M, Aigner M, et al. Increased expression of ALCAM/CD166 in pancreatic cancer is an independent prognostic marker for poor survival and early tumour relapse. Br J Cancer 2009; 101: 457-64.
Weidle UH, Eggle D, Klostermann S, Swart GW. ALCAM/CD166: cancer-related issues. Cancer. Genomics. Proteomics 2010; 7: 231-43.
Weichert W, Knosel T, Bellach J, Dietel M, Kristiansen G. ALCAM/CD166 is overexpressed in colorectal carcinoma and correlates with shortened patient survival. J Clin Pathol 2004; 57: 1160-4.
Wu Y, Zhou BP. Inflammation: a driving force speeds cancer metastasis. Cell Cycle 2009; 8: 3267-73.
Yekebas EF, Schurr PG, Kaifi JT, Link BC, Kutup A, Mann O, Wolfram L, Izbicki JR. Effectiveness of radical en-bloc-esophagectomy compared to transhiatal esophagectomy in squamous cell cancer of the esophagus is influenced by nodal micrometastases. J Surg Oncol 2006; 93: 541-9.
Ofori-Acquah SF, King JA. Activated leukocyte cell adhesion molecule: a new paradox in cancer. Transl Res 2008; 151: 122-8.
van den Brand M, Takes RP, Blokpoel-deRuyter M, Slootweg PJ, van Kempen LC. Activated leukocyte cell adhesion molecule expression predicts lymph node metastasis in oral squamous cell carcinoma. Oral Oncol 2010; 46: 393-8.
Scheunemann P, Izbicki JR, Pantel K. Tumorigenic potential of apparently tumor-free lymph nodes. N Engl J Med 1999; 340: 1687.
Kutup A, Link BC, Schurr PG, Strate T, Kaifi JT, Bubenheim M, Seewald S, Yekebas EF, Soehendra N, Izbicki JR. Quality control of endoscopic ultrasound in preoperative staging of esophageal cancer. Endoscopy 2007; 39: 715-9.
Kulasingam V, Zheng Y, Soosaipillai A, Leon AE, Gion M, Diamandis EP. Activated leukocyte cell adhesion molecule: a novel biomarker for breast cancer. Int J Cancer 2009; 125: 9-14.
Ladd J, Taylor AD, Piliarik M, Homola J, Jiang S. Label-free detection of cancer biomarker candidates using surface plasmon resonance imaging. Anal Bioanal Chem 2009; 393: 1157-63.
Verma A, Shukla NK, Deo SV, Gupta SD, Ralhan R. MEMD/ALCAM: a potential marker for tumor invasion and nodal metastasis in esophageal squamous cell carcinoma. Oncology 2005; 68: 462-70.
Kristiansen G, Pilarsky C, Wissmann C, Stephan C, Weissbach L, Loy V, Loening S, Dietel M, Rosenthal A. ALCAM/CD166 is up-regulated in low-grade prostate cancer and progressively lost in high-grade lesions. Prostate 2003; 54: 34-43.
Thorban S, Roder JD, Nekarda H, Funk A, Siewert JR, Pantel K. Immunocytochemical detection of disseminated tumor cells in the bone marrow of patients with esophageal carcinoma. J Natl Cancer Inst. 1996; 88: 1222-7.
Hyngstrom JR, Posner MC. Neoadjuvant strategies for the treatment of locally advanced esophageal cancer. J Surg Oncol 2010; 101: 299-304.
Weidle UH, Eggle D, Klostermann S. L1-CAM as a target for treatment of cancer with monoclonal antibodies. Anticancer Res 2009; 29: 4919-31.
Schlomm T, Iwers L, Kirstein P, Jessen B, Kollermann J, Minner S, Passow-Drolet A, Mirlacher M, Milde-Langosch K, Graefen M, Haese A, Steuber T, et al. Clinical significance of p53 alterations in surgically treated prostate cancers. Mod Pathol 2008; 21: 1371-8.
Kaifi JT, Yekebas EF, Schurr P, Obonyo D, Wachowiak R, Busch P, Heinecke A, Pantel K, Izbicki JR. Tumor-cell homing to lymph nodes and bone marrow and CXCR4 expression in esophageal cancer. J Natl Cancer Inst 2005; 97: 1840-7.
Altman DG, Lausen B, Sauerbrei W, Schumacher M. Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 1994; 86: 829-35.
Braun S, Pantel K, Muller P, Janni W, Hepp F, Kentenich CR, Gastroph S, Wischnik A, Dimpfl T, Kindermann G, Riethmuller G, Schlimok G. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I. II, or. III breast cancer. N Engl J Med 2000; 342: 525-33.
van Kilsdonk JW, Wilting RH, Bergers M, van Muijen GN, Schalkwijk J, van Kempen LC, Swart GW. Attenuation of melanoma invasion by a secreted variant of activated leukocyte cell adhesion molecule. Cancer Res 2008; 68: 3671-9.
2007; 39
2006; 93
2009; 24
2010; 19
2010; 127
2010; 101
2008; 14
1999; 340
2006; 19
2008; 13
2008; 248
2009; 393
2003; 54
2009; 29
2005; 68
1994; 86
2010; 46
2004; 57
2005; 97
2009; 101
2008; 68
2009; 8
2008; 21
2007; 5
2000; 342
2008; 112
2007; 20
2007; 66
2009; 16
2010; 7
2009; 125
2008; 151
1996; 88
e_1_2_6_31_2
e_1_2_6_30_2
e_1_2_6_19_2
Rawnaq T (e_1_2_6_20_2) 2009; 29
e_1_2_6_12_2
e_1_2_6_35_2
e_1_2_6_13_2
e_1_2_6_34_2
e_1_2_6_33_2
e_1_2_6_11_2
e_1_2_6_32_2
e_1_2_6_16_2
e_1_2_6_17_2
e_1_2_6_14_2
e_1_2_6_15_2
Weidle UH (e_1_2_6_10_2) 2010; 7
e_1_2_6_8_2
e_1_2_6_7_2
Weidle UH (e_1_2_6_18_2) 2009; 29
e_1_2_6_9_2
e_1_2_6_29_2
e_1_2_6_4_2
e_1_2_6_3_2
e_1_2_6_6_2
e_1_2_6_5_2
e_1_2_6_24_2
e_1_2_6_23_2
e_1_2_6_2_2
e_1_2_6_22_2
e_1_2_6_21_2
e_1_2_6_28_2
e_1_2_6_27_2
e_1_2_6_26_2
e_1_2_6_25_2
References_xml – reference: Weidle UH, Eggle D, Klostermann S, Swart GW. ALCAM/CD166: cancer-related issues. Cancer. Genomics. Proteomics 2010; 7: 231-43.
– reference: Kulasingam V, Zheng Y, Soosaipillai A, Leon AE, Gion M, Diamandis EP. Activated leukocyte cell adhesion molecule: a novel biomarker for breast cancer. Int J Cancer 2009; 125: 9-14.
– reference: Thorban S, Roder JD, Nekarda H, Funk A, Siewert JR, Pantel K. Immunocytochemical detection of disseminated tumor cells in the bone marrow of patients with esophageal carcinoma. J Natl Cancer Inst. 1996; 88: 1222-7.
– reference: Kalinina T, Bockhorn M, Kaifi JT, Thieltges S, Gungor C, Effenberger KE, Strelow A, Reichelt U, Sauter G, Pantel K, Izbicki JR, Yekebas EF. Insulin-like growth factor-1 receptor as a novel prognostic marker and its implication as a cotarget in the treatment of human adenocarcinoma of the esophagus. Int J Cancer 2010; 127: 1931-40.
– reference: Braun S, Pantel K, Muller P, Janni W, Hepp F, Kentenich CR, Gastroph S, Wischnik A, Dimpfl T, Kindermann G, Riethmuller G, Schlimok G. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I. II, or. III breast cancer. N Engl J Med 2000; 342: 525-33.
– reference: Yekebas EF, Schurr PG, Kaifi JT, Link BC, Kutup A, Mann O, Wolfram L, Izbicki JR. Effectiveness of radical en-bloc-esophagectomy compared to transhiatal esophagectomy in squamous cell cancer of the esophagus is influenced by nodal micrometastases. J Surg Oncol 2006; 93: 541-9.
– reference: Kutup A, Link BC, Schurr PG, Strate T, Kaifi JT, Bubenheim M, Seewald S, Yekebas EF, Soehendra N, Izbicki JR. Quality control of endoscopic ultrasound in preoperative staging of esophageal cancer. Endoscopy 2007; 39: 715-9.
– reference: Shimpi RA, George J, Jowell P, Gress FG. Staging of esophageal cancer by EUS: staging accuracy revisited. Gastrointest Endosc 2007; 66: 475-82.
– reference: Scheunemann P, Izbicki JR, Pantel K. Tumorigenic potential of apparently tumor-free lymph nodes. N Engl J Med 1999; 340: 1687.
– reference: van Kilsdonk JW, Wilting RH, Bergers M, van Muijen GN, Schalkwijk J, van Kempen LC, Swart GW. Attenuation of melanoma invasion by a secreted variant of activated leukocyte cell adhesion molecule. Cancer Res 2008; 68: 3671-9.
– reference: Ihnen M, Muller V, Wirtz RM, Schroder C, Krenkel S, Witzel I, Lisboa BW, Janicke F, Milde-Langosch K. Predictive impact of activated leukocyte cell adhesion molecule (ALCAM/CD166) in breast cancer. Breast Cancer Res Treat 2008; 112: 419-27.
– reference: Stoecklein NH, Hosch SB, Bezler M, Stern F, Hartmann CH, Vay C, Siegmund A, Scheunemann P, Schurr P, Knoefel WT, Verde PE, Reichelt U, et al. Direct genetic analysis of single disseminated cancer cells for prediction of outcome and therapy selection in esophageal cancer. Cancer Cell 2008; 13: 441-53.
– reference: Altman DG, Lausen B, Sauerbrei W, Schumacher M. Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 1994; 86: 829-35.
– reference: Kristiansen G, Pilarsky C, Wissmann C, Stephan C, Weissbach L, Loy V, Loening S, Dietel M, Rosenthal A. ALCAM/CD166 is up-regulated in low-grade prostate cancer and progressively lost in high-grade lesions. Prostate 2003; 54: 34-43.
– reference: Vaisocherova H, Faca VM, Taylor AD, Hanash S, Jiang S. Comparative study of SPR and ELISA methods based on analysis of CD166/ALCAM levels in cancer and control human sera. Biosens Bioelectron 2009; 24: 2143-8.
– reference: Wu Y, Zhou BP. Inflammation: a driving force speeds cancer metastasis. Cell Cycle 2009; 8: 3267-73.
– reference: Rosso O, Piazza T, Bongarzone I, Rossello A, Mezzanzanica D, Canevari S, Orengo AM, Puppo A, Ferrini S, Fabbi M. The ALCAM shedding by the metalloprotease ADAM17/TACE is involved in motility of ovarian carcinoma cells. Mol Cancer Res 2007; 5: 1246-53.
– reference: Weidle UH, Eggle D, Klostermann S. L1-CAM as a target for treatment of cancer with monoclonal antibodies. Anticancer Res 2009; 29: 4919-31.
– reference: Schlomm T, Iwers L, Kirstein P, Jessen B, Kollermann J, Minner S, Passow-Drolet A, Mirlacher M, Milde-Langosch K, Graefen M, Haese A, Steuber T, et al. Clinical significance of p53 alterations in surgically treated prostate cancers. Mod Pathol 2008; 21: 1371-8.
– reference: Mezzanzanica D, Fabbi M, Bagnoli M, Staurengo S, Losa M, Balladore E, Alberti P, Lusa L, Ditto A, Ferrini S, Pierotti MA, Barbareschi M, et al. Subcellular localization of activated leukocyte cell adhesion molecule is a molecular predictor of survival in ovarian carcinoma patients. Clin Cancer Res 2008; 14: 1726-33.
– reference: Rawnaq T, Kleinhans H, Uto M, Schurr PG, Reichelt U, Cataldegirmen G, Gawad KA, Yekebas EF, Schachner M, Izbicki JR, Kaifi JT. Subset of esophageal adenocarcinoma expresses adhesion molecule l1 in contrast to squamous cell carcinoma. Anticancer Res 2009; 29: 1195-9.
– reference: Koenig AM, Prenzel KL, Bogoevski D, Yekebas EF, Bubenheim M, Faithova L, Vashist YK, Gawad KA, Baldus SE, Pantel K, Schneider PM, Holscher AH, et al. Strong impact of micrometastatic tumor cell load in patients with esophageal carcinoma. Ann Surg Oncol 2009; 16: 454-62.
– reference: Reichelt U, Duesedau P, Tsourlakis M, Quaas A, Link BC, Schurr PG, Kaifi JT, Gros SJ, Yekebas EF, Marx A, Simon R, Izbicki JR, et al. Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol 2007; 20: 120-9.
– reference: Ladd J, Taylor AD, Piliarik M, Homola J, Jiang S. Label-free detection of cancer biomarker candidates using surface plasmon resonance imaging. Anal Bioanal Chem 2009; 393: 1157-63.
– reference: Barnett SA, Rizk NP. Randomized clinical trials in esophageal carcinoma. Surg Oncol Clin N Am 2010; 19: 59-80.
– reference: Weichert W, Knosel T, Bellach J, Dietel M, Kristiansen G. ALCAM/CD166 is overexpressed in colorectal carcinoma and correlates with shortened patient survival. J Clin Pathol 2004; 57: 1160-4.
– reference: Kahlert C, Weber H, Mogler C, Bergmann F, Schirmacher P, Kenngott HG, Matterne U, Mollberg N, Rahbari NN, Hinz U, Koch M, Aigner M, et al. Increased expression of ALCAM/CD166 in pancreatic cancer is an independent prognostic marker for poor survival and early tumour relapse. Br J Cancer 2009; 101: 457-64.
– reference: Verma A, Shukla NK, Deo SV, Gupta SD, Ralhan R. MEMD/ALCAM: a potential marker for tumor invasion and nodal metastasis in esophageal squamous cell carcinoma. Oncology 2005; 68: 462-70.
– reference: van den Brand M, Takes RP, Blokpoel-deRuyter M, Slootweg PJ, van Kempen LC. Activated leukocyte cell adhesion molecule expression predicts lymph node metastasis in oral squamous cell carcinoma. Oral Oncol 2010; 46: 393-8.
– reference: Ofori-Acquah SF, King JA. Activated leukocyte cell adhesion molecule: a new paradox in cancer. Transl Res 2008; 151: 122-8.
– reference: Peyre CG, Hagen JA, DeMeester SR, Van Lanschot JJ, Holscher A, Law S, Ruol A, Ancona E, Griffin SM, Altorki NK, Rice TW, Wong J, et al. Predicting systemic disease in patients with esophageal cancer after esophagectomy: a multinational study on the significance of the number of involved lymph nodes. Ann Surg 2008; 248: 979-85.
– reference: Hyngstrom JR, Posner MC. Neoadjuvant strategies for the treatment of locally advanced esophageal cancer. J Surg Oncol 2010; 101: 299-304.
– reference: Kaifi JT, Strelow A, Schurr PG, Reichelt U, Yekebas EF, Wachowiak R, Quaas A, Strate T, Schaefer H, Sauter G, Schachner M, Izbicki JR. L1 (CD171) is highly expressed in gastrointestinal stromal tumors. Mod Pathol 2006; 19: 399-406.
– reference: Kaifi JT, Yekebas EF, Schurr P, Obonyo D, Wachowiak R, Busch P, Heinecke A, Pantel K, Izbicki JR. Tumor-cell homing to lymph nodes and bone marrow and CXCR4 expression in esophageal cancer. J Natl Cancer Inst 2005; 97: 1840-7.
– volume: 151
  start-page: 122
  year: 2008
  end-page: 8
  article-title: Activated leukocyte cell adhesion molecule: a new paradox in cancer
  publication-title: Transl Res
– volume: 5
  start-page: 1246
  year: 2007
  end-page: 53
  article-title: The ALCAM shedding by the metalloprotease ADAM17/TACE is involved in motility of ovarian carcinoma cells
  publication-title: Mol Cancer Res
– volume: 88
  start-page: 1222
  year: 1996
  end-page: 7
  article-title: Immunocytochemical detection of disseminated tumor cells in the bone marrow of patients with esophageal carcinoma
  publication-title: J Natl Cancer Inst.
– volume: 393
  start-page: 1157
  year: 2009
  end-page: 63
  article-title: Label‐free detection of cancer biomarker candidates using surface plasmon resonance imaging
  publication-title: Anal Bioanal Chem
– volume: 54
  start-page: 34
  year: 2003
  end-page: 43
  article-title: ALCAM/CD166 is up‐regulated in low‐grade prostate cancer and progressively lost in high‐grade lesions
  publication-title: Prostate
– volume: 101
  start-page: 299
  year: 2010
  end-page: 304
  article-title: Neoadjuvant strategies for the treatment of locally advanced esophageal cancer
  publication-title: J Surg Oncol
– volume: 19
  start-page: 399
  year: 2006
  end-page: 406
  article-title: L1 (CD171) is highly expressed in gastrointestinal stromal tumors
  publication-title: Mod Pathol
– volume: 24
  start-page: 2143
  year: 2009
  end-page: 8
  article-title: Comparative study of SPR and ELISA methods based on analysis of CD166/ALCAM levels in cancer and control human sera
  publication-title: Biosens Bioelectron
– volume: 66
  start-page: 475
  year: 2007
  end-page: 82
  article-title: Staging of esophageal cancer by EUS: staging accuracy revisited
  publication-title: Gastrointest Endosc
– volume: 68
  start-page: 3671
  year: 2008
  end-page: 9
  article-title: Attenuation of melanoma invasion by a secreted variant of activated leukocyte cell adhesion molecule
  publication-title: Cancer Res
– volume: 29
  start-page: 1195
  year: 2009
  end-page: 9
  article-title: Subset of esophageal adenocarcinoma expresses adhesion molecule l1 in contrast to squamous cell carcinoma
  publication-title: Anticancer Res
– volume: 125
  start-page: 9
  year: 2009
  end-page: 14
  article-title: Activated leukocyte cell adhesion molecule: a novel biomarker for breast cancer
  publication-title: Int J Cancer
– volume: 93
  start-page: 541
  year: 2006
  end-page: 9
  article-title: Effectiveness of radical en‐bloc‐esophagectomy compared to transhiatal esophagectomy in squamous cell cancer of the esophagus is influenced by nodal micrometastases
  publication-title: J Surg Oncol
– volume: 21
  start-page: 1371
  year: 2008
  end-page: 8
  article-title: Clinical significance of p53 alterations in surgically treated prostate cancers
  publication-title: Mod Pathol
– volume: 20
  start-page: 120
  year: 2007
  end-page: 9
  article-title: Frequent homogeneous HER‐2 amplification in primary and metastatic adenocarcinoma of the esophagus
  publication-title: Mod Pathol
– volume: 19
  start-page: 59
  year: 2010
  end-page: 80
  article-title: Randomized clinical trials in esophageal carcinoma
  publication-title: Surg Oncol Clin N Am
– volume: 127
  start-page: 1931
  year: 2010
  end-page: 40
  article-title: Insulin‐like growth factor‐1 receptor as a novel prognostic marker and its implication as a cotarget in the treatment of human adenocarcinoma of the esophagus
  publication-title: Int J Cancer
– volume: 14
  start-page: 1726
  year: 2008
  end-page: 33
  article-title: Subcellular localization of activated leukocyte cell adhesion molecule is a molecular predictor of survival in ovarian carcinoma patients
  publication-title: Clin Cancer Res
– volume: 340
  start-page: 1687
  year: 1999
  article-title: Tumorigenic potential of apparently tumor‐free lymph nodes
  publication-title: N Engl J Med
– volume: 101
  start-page: 457
  year: 2009
  end-page: 64
  article-title: Increased expression of ALCAM/CD166 in pancreatic cancer is an independent prognostic marker for poor survival and early tumour relapse
  publication-title: Br J Cancer
– volume: 13
  start-page: 441
  year: 2008
  end-page: 53
  article-title: Direct genetic analysis of single disseminated cancer cells for prediction of outcome and therapy selection in esophageal cancer
  publication-title: Cancer Cell
– volume: 68
  start-page: 462
  year: 2005
  end-page: 70
  article-title: MEMD/ALCAM: a potential marker for tumor invasion and nodal metastasis in esophageal squamous cell carcinoma
  publication-title: Oncology
– volume: 248
  start-page: 979
  year: 2008
  end-page: 85
  article-title: Predicting systemic disease in patients with esophageal cancer after esophagectomy: a multinational study on the significance of the number of involved lymph nodes
  publication-title: Ann Surg
– volume: 7
  start-page: 231
  year: 2010
  end-page: 43
  article-title: ALCAM/CD166: cancer‐related issues
  publication-title: Cancer. Genomics. Proteomics
– volume: 112
  start-page: 419
  year: 2008
  end-page: 27
  article-title: Predictive impact of activated leukocyte cell adhesion molecule (ALCAM/CD166) in breast cancer
  publication-title: Breast Cancer Res Treat
– volume: 97
  start-page: 1840
  year: 2005
  end-page: 7
  article-title: Tumor‐cell homing to lymph nodes and bone marrow and CXCR4 expression in esophageal cancer
  publication-title: J Natl Cancer Inst
– volume: 57
  start-page: 1160
  year: 2004
  end-page: 4
  article-title: ALCAM/CD166 is overexpressed in colorectal carcinoma and correlates with shortened patient survival
  publication-title: J Clin Pathol
– volume: 342
  start-page: 525
  year: 2000
  end-page: 33
  article-title: Cytokeratin‐positive cells in the bone marrow and survival of patients with stage I. II, or. III breast cancer
  publication-title: N Engl J Med
– volume: 86
  start-page: 829
  year: 1994
  end-page: 35
  article-title: Dangers of using “optimal” cutpoints in the evaluation of prognostic factors
  publication-title: J Natl Cancer Inst
– volume: 29
  start-page: 4919
  year: 2009
  end-page: 31
  article-title: L1‐CAM as a target for treatment of cancer with monoclonal antibodies
  publication-title: Anticancer Res
– volume: 8
  start-page: 3267
  year: 2009
  end-page: 73
  article-title: Inflammation: a driving force speeds cancer metastasis
  publication-title: Cell Cycle
– volume: 16
  start-page: 454
  year: 2009
  end-page: 62
  article-title: Strong impact of micrometastatic tumor cell load in patients with esophageal carcinoma
  publication-title: Ann Surg Oncol
– volume: 39
  start-page: 715
  year: 2007
  end-page: 9
  article-title: Quality control of endoscopic ultrasound in preoperative staging of esophageal cancer
  publication-title: Endoscopy
– volume: 46
  start-page: 393
  year: 2010
  end-page: 8
  article-title: Activated leukocyte cell adhesion molecule expression predicts lymph node metastasis in oral squamous cell carcinoma
  publication-title: Oral Oncol
– volume: 29
  start-page: 4919
  year: 2009
  ident: e_1_2_6_18_2
  article-title: L1‐CAM as a target for treatment of cancer with monoclonal antibodies
  publication-title: Anticancer Res
– ident: e_1_2_6_24_2
  doi: 10.1038/modpathol.3800712
– ident: e_1_2_6_33_2
  doi: 10.1016/j.oraloncology.2010.03.001
– ident: e_1_2_6_30_2
  doi: 10.1159/000086989
– volume: 7
  start-page: 231
  year: 2010
  ident: e_1_2_6_10_2
  article-title: ALCAM/CD166: cancer‐related issues
  publication-title: Cancer. Genomics. Proteomics
– ident: e_1_2_6_32_2
  doi: 10.1002/pros.10161
– ident: e_1_2_6_11_2
  doi: 10.1016/j.trsl.2007.09.006
– ident: e_1_2_6_17_2
  doi: 10.1158/1541-7786.MCR-07-0060
– ident: e_1_2_6_21_2
  doi: 10.1016/j.bios.2008.11.015
– ident: e_1_2_6_7_2
  doi: 10.1097/SLA.0b013e3181904f3c
– ident: e_1_2_6_9_2
  doi: 10.1016/j.gie.2007.03.1051
– ident: e_1_2_6_26_2
  doi: 10.1056/NEJM199905273402116
– ident: e_1_2_6_28_2
  doi: 10.1016/j.ccr.2008.04.005
– ident: e_1_2_6_6_2
  doi: 10.1016/j.soc.2009.09.007
– ident: e_1_2_6_27_2
  doi: 10.1056/NEJM200002243420801
– ident: e_1_2_6_25_2
  doi: 10.1002/ijc.25196
– ident: e_1_2_6_3_2
  doi: 10.1245/s10434-008-0169-7
– ident: e_1_2_6_16_2
  doi: 10.1038/sj.bjc.6605136
– ident: e_1_2_6_35_2
  doi: 10.1093/jnci/88.17.1222
– ident: e_1_2_6_23_2
  doi: 10.1007/s00216-008-2448-3
– ident: e_1_2_6_12_2
  doi: 10.1158/0008-5472.CAN-07-5767
– ident: e_1_2_6_22_2
  doi: 10.1002/ijc.24292
– ident: e_1_2_6_31_2
  doi: 10.4161/cc.8.20.9699
– ident: e_1_2_6_29_2
  doi: 10.1093/jnci/86.11.829
– ident: e_1_2_6_34_2
  doi: 10.1038/modpathol.2008.104
– ident: e_1_2_6_2_2
  doi: 10.1002/jso.20544
– ident: e_1_2_6_4_2
  doi: 10.1093/jnci/dji431
– ident: e_1_2_6_5_2
  doi: 10.1002/jso.21479
– volume: 29
  start-page: 1195
  year: 2009
  ident: e_1_2_6_20_2
  article-title: Subset of esophageal adenocarcinoma expresses adhesion molecule l1 in contrast to squamous cell carcinoma
  publication-title: Anticancer Res
– ident: e_1_2_6_14_2
  doi: 10.1136/jcp.2004.016238
– ident: e_1_2_6_8_2
  doi: 10.1055/s-2007-966655
– ident: e_1_2_6_13_2
  doi: 10.1007/s10549-007-9879-y
– ident: e_1_2_6_15_2
  doi: 10.1158/1078-0432.CCR-07-0428
– ident: e_1_2_6_19_2
  doi: 10.1038/modpathol.3800547
SSID ssj0011504
Score 2.256428
Snippet The expression of the activated leukocyte cell adhesion molecule (ALCAM and CD166) is increased in various types of cancer. We aimed to evaluate its role as a...
SourceID proquest
pubmed
pascalfrancis
crossref
wiley
istex
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 396
SubjectTerms Activated-Leukocyte Cell Adhesion Molecule - blood
Activated-Leukocyte Cell Adhesion Molecule - metabolism
Adult
Aged
Aged, 80 and over
ALCAM
Biological and medical sciences
biomarker
Biomarkers
Biomarkers, Tumor - blood
Biomarkers, Tumor - metabolism
Bone marrow
Cancer
Esophageal cancer
Esophageal Neoplasms - metabolism
Esophageal Neoplasms - mortality
Esophageal Neoplasms - pathology
Esophagus
Female
Gastroenterology. Liver. Pancreas. Abdomen
Humans
Immunohistochemistry
Keratins - analysis
Male
Medical research
Medical sciences
Middle Aged
Mortality
Multivariate analysis
Neoplasm Grading
Prognosis
Protein Array Analysis
Retrospective Studies
Tumors
Title ALCAM (CD166) expression and serum levels are markers for poor survival of esophageal cancer patients
URI https://api.istex.fr/ark:/67375/WNG-BXNF32WG-L/fulltext.pdf
https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fijc.26377
https://www.ncbi.nlm.nih.gov/pubmed/21858815
https://www.proquest.com/docview/1433119019
https://www.proquest.com/docview/1015755526
Volume 131
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9RAEF9KBfHF-t1oLauI1Idcs5_Zw6fz6rWW9h7E0nsQwn4daNtcuVyg-Nc7u_koJxXEl5Cws4Gdndn8Jjv7G4TeZUTLnMss5Y66lFMrUs29Sh1Xhg2NcUxHts-pPDrjxzMx20Afu7MwDT9E_8MteEZcr4ODa1Pt35KG_vhpB1SyPJwkJ0wG3vyDrz11VAA6LQNzlkIgJjtWoYzu9z3XvkX3glpvQm6krkA986auxV3Acx3Hxg_RZAt974bQ5J9cDOqVGdhff7A7_ucYH6GHLUDFo8aiHqMNXz5B90_bLfinyI9OxqNTvDc-IFJ-wP6mzaQtsS4dBoOur_BlyESqsF56fBXSf5YVBmyMrxdwqWpYnMC88WKOfaihAAsaPNlgfSDS0LxWz9DZ5PO38VHa1mpILYQ8eeoVYcRnWkO4YplzmTFKaOEtsw783BoIlaRmWueWW-6504wLPyQqk46ynLHnaLNclH4bYT6XmVehzpVwADe0pmIOuI94PYT3OJOgvW7WCtsSmYd6GpdFQ8FMC1BbEdWWoLe96HXD3nGX0Ps49b0EKCaku-WiOJ8eFp9m0wmj54fFSYJ212yj7wAhpCI5GyZopzOWol0KKoitGCMBdkHzm74ZnDjszOjSL-oq5NkBbBaCygS9aIzs9uWAqJQiAoYdTeXvAym-HI_jzct_F32FHgAEjAnIROygzdWy9q8BZq3MbvSn34IrILs
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swED-6Fra97PvDW9dpY4z2wallfdiBvWTZ0rRL8jBampchZEmBdq1T4hjK_vqdbMclo4OxF2Ojk0GnO_l30vl3AB8iqmXCZRRyG9uQx0aEmrs0tDzNWDfLLNMV2-dEDk_40VRMN-DT6l-Ymh-i3XDznlGt197B_Yb0_g1r6Nm56cSSJckd2KrO5zwk-t6SR3mo03AwRyGGYnLFKxTF-23Xta_Rllfstc-O1AUqaFZXtrgNeq4j2epTNHgIP1aDqDNQfnbKZdYxv_7gd_zfUT6CBw1GJb3aqB7DhsufwN1xcwr_FFxv1O-NyW7_C5Vyj7jrJpk2Jzq3BG26vCQXPhmpIHrhyKXPAFoUBOExuZrjpShxfUILJ_MZcb6MAq5p-GS8AaJIzfRaPIOTwdfj_jBsyjWEBqOeJHQpZdRFWmPEYpi1UZalQgtnmLHo6ibDaElqpnViuOGOW824cF2aRtLGLGHsOWzm89y9BMJnMnKpL3UlLCIOrWMxQ-hHne7ie2wWwO5q2pRpuMx9SY0LVbMwxwrVpiq1BfC-Fb2qCTxuE_pYzX0rgYrxGW-JUKeTA_V5Ohmw-PRAjQLYWTOOtgNGkSlNWDeA7ZW1qGY1KDC8Yox65IXN79pm9GN_OKNzNy8Ln2qHyFmIWAbworaym5cjqEpTKnDYla38fSDq8Khf3bz6d9G3cG94PB6p0eHk22u4j4iwykemYhs2l4vSvUHUtcx2Kuf6DYMMJNk
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9RAFB5qC8UX75doraOI1IdsM9dk8WnddXtxu4hYug_CMJmZQGubXTYbKP56z-RWViqILyEhJwlzcs7kO8mX7yD0LiJaxlxGIbfUhpwaEWruktDyJGX9NLVMV2qfU3l4yo9nYraBPrb_wtT6EN0LN58Z1XztE3xhs_0b0dDzC9OjksXxHbQFF6OezzX61mlHeaTTSDBHIVRispUViuh-d-jaw2jL-_XakyN1Af7J6sYWtyHPdSBbPYnG99GPdgw1AeVnr1ylPfPrD3nH_xzkA3SvQah4UIfUQ7Th8kdo-6T5Bv8YucFkODjBe8MRkfIDdtcNlTbHOrcYIrq8wpeeilRgvXT4yvN_lgUGcIwXc1gUJcxOEN94nmHnmyjAjAZbxocfmNQ6r8UTdDr-_H14GDbNGkIDNU8cuoQw4iKtoV4xzNooTROhhTPMWEh0k0KtJDXTOjbccMetZly4PkkiaSmLGXuKNvN57p4jzDMZucQ3uhIW8IbWVGQA_IjTfTiPTQO01941ZRolc99Q41LVGsxUgdtU5bYAve1MF7V8x21G76tb31mAYzzfLRbqbHqgPs2mY0bPDtQkQLtrsdEdADVkQmLWD9BOGyyqmQsKKK4YIx53we433W7IYv9pRuduXhaeaAe4WQgqA_SsDrKbkwOkShIiYNhVqPx9IOroeFitvPh309do--torCZH0y8v0V2AgxUZmYgdtLlalu4VQK5Vulul1m_3HiOI
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=ALCAM+%28CD166%29+expression+and+serum+levels+are+markers+for+poor+survival+of+esophageal+cancer+patients&rft.jtitle=International+journal+of+cancer&rft.au=Tachezy%2C+Michael&rft.au=Effenberger%2C+Katharina&rft.au=Zander%2C+Hilke&rft.au=Minner%2C+Sarah&rft.date=2012-07-15&rft.pub=Wiley+Subscription+Services%2C+Inc.%2C+A+Wiley+Company&rft.issn=0020-7136&rft.eissn=1097-0215&rft.volume=131&rft.issue=2&rft.spage=396&rft.epage=405&rft_id=info:doi/10.1002%2Fijc.26377&rft.externalDBID=10.1002%252Fijc.26377&rft.externalDocID=IJC26377
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0020-7136&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0020-7136&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0020-7136&client=summon